A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche : biologic and clinical applications by Jakubikova, Jana et al.
Oncotarget77326www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 47
A novel 3D mesenchymal stem cell model of the multiple 
myeloma bone marrow niche: biologic and clinical applications
Jana Jakubikova1,2,3, Danka Cholujova3, Teru Hideshima1,2, Paulina Gronesova3, 
Andrea Soltysova4, Takeshi Harada1,2, Jungnam Joo5, Sun-Young Kong6, Raphael 
E. Szalat1,2, Paul G. Richardson1,2, Nikhil C. Munshi1,2, David M. Dorfman7,2, 
Kenneth C. Anderson1,2
1Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Department of 
Medical Oncology, Boston, MA, USA
2Department of Medicine, Harvard Medical School, Boston, MA, USA
3Cancer Research Institute, Biomedical Research Center SAS, Bratislava, Slovak Republic
4Department of Molecular Biology, Faculty of Natural Sciences, Comenius University, Bratislava, Slovak Republic
5Biometric Research Branch, Division of Cancer Epidemiology and Prevention, Research Institute & Hospital, National Cancer 
Center, Goyang-si Gyeonggi-do, South Korea
6Department of Laboratory Medicine and Translational Epidemiology Branch, Research Institute & Hospital, National Cancer 
Center, Goyang-si Gyeonggi-do, South Korea
7Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA
Correspondence to: Kenneth C. Anderson, email: kenneth_anderson@dfci.harvard.edu
Jana Jakubikova, email: jana_jakubikova@dfci.harvard.edu
Keywords: multiple myeloma, tumor microenvironment, mesenchymal stem cells, 3D model, drug resistance
Received: July 06, 2016    Accepted: September 28, 2016    Published: October 13, 2016
ABSTRACT
Specific niches within the tumor bone marrow (BM) microenvironment afford a 
sanctuary for multiple myeloma (MM) clones due to stromal cell-tumor cell interactions, 
which confer survival advantage and drug resistance. Defining the sequelae of tumor 
cell interactions within the MM niches on an individualized basis may provide the 
rationale for personalized therapies. To mimic the MM niche, we here describe a new 
3D co-culture ex-vivo model in which primary MM patient BM cells are co-cultured with 
mesenchymal stem cells (MSC) in a hydrogel 3D system. In the 3D model, MSC with 
conserved phenotype (CD73+CD90+CD105+) formed compact clusters with active 
fibrous connections, and retained lineage differentiation capacity. Extracellular matrix 
molecules, integrins, and niche related molecules including N-cadherin and CXCL12 are 
expressed in 3D MSC model. Furthermore, activation of osteogenesis (MMP13, SPP1, 
ADAMTS4, and MGP genes) and osteoblastogenic differentiation was confirmed in 3D 
MSC model. Co-culture of patient-derived BM mononuclear cells with either autologous 
or allogeneic MSC in 3D model increased proliferation of MM cells, CXCR4 expression, 
and SP cells. We carried out immune profiling to show that distribution of immune 
cell subsets was similar in 3D and 2D MSC model systems. Importantly, resistance to 
novel agents (IMiDs, bortezomib, carfilzomib) and conventional agents (doxorubicin, 
dexamethasone, melphalan) was observed in 3D MSC system, reflective of clinical 
resistance. This 3D MSC model may therefore allow for studies of MM pathogenesis 
and drug resistance within the BM niche. Importantly, ongoing prospective trials are 
evaluating its utility to inform personalized targeted and immune therapy in MM.
INTRODUCTION
Multiple myeloma (MM) is a hematological 
malignancy characterized by accumulation of malignant 
plasma cells (PC) in the bone marrow (BM) [1]. In 
addition to genetic anomalies intrinsic to MM clones, 
malignant PCs are also influenced by their tumor 
microenvironment [2]. In particular, fibroblast/stromal-
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like cells, endothelial cells, immune cells, and the extra-
cellular matrix profoundly contribute the behavior of MM 
cells. Indeed the bidirectional interaction between MM 
cells and their supporting stromal cells plays a central 
role in myelomagenesis, mediating resistance to cell 
death, sustained proliferation, cell homing and invasion, 
immunosuppression, stemness and self-renewal, as well 
as angiogenesis, thereby promoting MM progression [3, 
4]. Characterizing the efficacy of novel agents therefore 
should not only assess impact on myeloma cells, but also 
define effects on the tumor microenvironment.
Specific niches within the tumor microenvironment 
afford a sanctuary for MM clones due to stromal cell-tumor 
cell interactions, which confer a survival advantage and 
drug resistance [4, 5]. Similarities in regulatory signaling 
molecules and the cell-cell crosstalk interactions between 
the normal hematopoietic stem cell (HSC) niche and the 
myeloma niche have been reported [6, 7]. Key common 
signaling pathways and molecules in both niches include: 
CXCL12/CXCR4 axis mediating homing and maintenance 
of HSC/MM cells; IL-6 signaling mediating growth and 
survival of HSC/MM cells; as well as VCAM1/VLA-
4 axis for retention of HSC/MM cells [8–10]. Further 
defining phenotypic features and molecular signatures 
of tumor cells in the myeloma niche will provide the 
framework for development of new treatment strategies 
targeting the sequelae of MM interactions with the BM 
milieu.
Several preclinical studies have demonstrated 
promise of novel anti-MM agents, which has not translated 
to clinical benefit. This may be due to unfavorable 
drug pharmacokinetics, but may reflect limitations in 
drug testing without the tumor microenvironment and/
or lack of 3 dimensional (3D) BM architecture [11, 
12]. The importance of using in vitro 3D, rather than 
2-dimentional (2D), models to create an experimental 
system recapitulating the specialized properties of the MM 
BM has been demonstrated using: ECM molecules such 
as collagen and/or fibronectin [13]; specialized scaffolds 
including gelatin sponges [14] or silk [15]; microfluidic 
ossified tissues such as osteoblast or plasma [16, 17], as 
well as RCCS™ bioreactor-based cultures [18]. However, 
additional studies are needed to closely mimic and 
investigate the myeloma niche.
Here we introduce a new 3D co-culture ex-vivo 
model to mimic the myeloma niche composed of non-
hematopoietic MM-associated mesenchymal stem 
cells, also known as multipotent stromal cells (MSC), 
imbedded in a hydrogel 3D system and co-cultured with 
primary MM patient cells. This model allows for study 
of cellular components in the myeloma niche including 
hematopoietic, immune, and tumor cells. In this study, we 
investigated the role of the tumor microenvironment in the 
pathogenesis of MM and drug resistance using this 3D co-
culture system of MSC with patient BM cells and MM 
cells. We demonstrated that this 3D co-culture ex-vivo 
system is useful for (i) study of the myeloma biology, 
especially mechanisms of drug resistance; (ii) evaluation 
of immune cell subset suppression; (iii) definition 
of efficacy of anti-MM/experimental drugs; and (iv) 
evaluation of treatment efficacy against individual patient 
MM cells to facilitate personalized targeted therapy.
RESULTS
Generation of 3D MSC model
To study mesenchymal stem cells/multipotent 
stromal cells (MSC) at different stages of MM (Figure 1A, 
ii), we used a multicolor flow cytometry panel to identify 
cells lacking human lineage markers (CD2, CD3, 
CD14, CD16, CD19, CD56, CD235a), CD45, CD34 
and HLA-DR, but expressing CD73, CD90 and CD105. 
The percentage of MSCs population was compared in 
smoldering MM (SMM), newly diagnosed MM (ND), 
relapsed (REL), and relapsed/refractory (REF) MM 
(Figure 1B). Interestingly, the MSC population increased 
in relapsed and relapsed/refractory MM patient samples. 
To mimic the neoplastic BM microenvironment of MM, 
we established a novel model of the marrow niche by 
culturing MM patient-derived MSC ex-vivo in a hydrogel-
based 3D model (3D MSC) compared with conventional 
monolayer culture (2D MSC; Figure 1C). In the 3D 
model, MSC formed compact clusters with active fibrous 
connections at day 3 to 5 (Figure 1D).
3D MSC conserve MSC-specific phenotype and 
undergo lineage differentiation capacity
MSC are known for the specific phenotype by 
co-expression of CD73, CD90, and CD105 [19]. MM 
patient-derived MSC clusters in 3D models highly 
expressed CD73, CD90, and CD105, as did MSC in 2D 
model (Figure 2A). Of note, MSC in 3D models revealed 
significantly decreased expression of CD271 and CD146 
than in 2D models (Figure 2B), whereas expression of 
HLA-ABC and CD166 was similar, only with minimal 
increases in mean fluorescence intensity in 3D vs 2D 
models. To assess the differentiation potential of these 
models, we cultured MSC in 3D versus 2D models with 
differentiation media towards osteogenic and adipogenic 
lineages. After culture in adipogenic differentiation media 
for 14 days, MSC in both 3D and 2D cultures efficiently 
differentiated into the adipogenic lineage, evidenced 
by Oil Red staining of lipid droplets in the cytoplasm 
(Figure 2C). Similarly, MSC grown in 2D versus 3D 
models with osteoblastogenic media for 21 days formed 
osteoblasts with extensive calcium mineralized matrix, 
evidenced by Alizarin red staining (Figure 2D). Moreover, 
low levels of calcium mineralization of clusters were 
observed in 3D model, even without osteoblastogenic 
media. We also assessed production of osteopontin (OPN) 
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and angiopoietin-2 (Ang-2) using multiplex luminex 
technology. OPN and Ang-2 production was significantly 
higher in 3D versus 2D MSC models (Figure 2E).
3D MSC increase neoplastic BM 
microenvironment
Previous studies suggest that MSCs modulate 
the MM BM microenvironment by modifying cytokine 
production [2]. We hypothesized that cytokine 
secretion by 3D MSC would enhance their ability to 
support MM cell growth. We measured production of 
cytokines, chemokines, and growth factors implicated 
in MM pathogenesis using multiple luminex analysis. 
Significantly higher production of interleukin 6 (IL-6), 
interleukin 8 (IL-8), monocyte chemotactic and activating 
factor (MCP-1), insulin-like growth factor binding protein 
1 (IGFBP-1), hepatocyte growth factor (HGF), and 
vascular endothelial growth factor (VEGF) was observed 
in 3D versus 2D MSC models (Figure 3A).
3D MSC express ECM- and integrin-rich 
microenvironment
Because the stem cell niche is enriched with 
extracellular matrix (ECM) molecules promoting 
expansion of the stem cell pool, we next studied 
ECM expression in these models. Significantly higher 
expression of ECM molecules including fibronectin, 
laminin, vitronectin, collagen IV, and collagen I was 
evident in 3D versus 2D MSC models, as determined by 
confocal microscopy analysis (Figure 3B, left). Similarly, 
in 5 day cultures of MM patient-derived MSC, we 
observed statistically significantly higher levels of ECM 
Figure 1: Generation of 3D vs 2D MSC models. A. Illustration of i) BM aspirate collection, ii) MSC evaluation, iii) BM processing, 
and iv) MSC expansion. B. The distribution of mesenchymal stem cells/multipotent stromal cells (MSC) defined by CD73, CD90 and 
CD105 profiling was determined in smoldering MM (SMM), newly diagnosed MM (ND), relapsed MM (REL) and relapsed/refractory MM 
(REF) patient samples by flow cytometry (p=0.563; Kruskal-Wallis one way analysis of variance of ranks). C. Generation of conventional 
monolayer 2D and 3D hydrogel-based MSC models. D. A representative picture of MM patient-derived MSC morphology generated in 3D 
model (right image) compared to monolayer 2D culture (left image) for 5 days. The images were captured with a Leica DFC300Fx camera 
on an inverted phase contrast Leica microscope using 10X objective and Leica IM50 image-acquisition software Version 4.
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Figure 2: MSC phenotype and lineage differentiation capacity in 3D vs 2D MSC models. A. Expression (histograms) and 
mean fluorescence intensity (MFI) of MSC specific markers CD73, CD90, and CD105 on MSC from 52 MM patients after culture for 5 days 
in 2D or 3D models was assessed by flow cytometry. B. Mean fluorescence intensity (MFI) and expression of CD271, CD146, HLA-ABC, 
and CD166 on MSC in 2D or 3D models was analyzed by flow cytometry. C. Representative images of lineage differentiation of MSC in 
2D and 3D models are shown. MM patient-derived MSC from 16 MM patients were cultured in either regular media (undifferentiated; left 
images) or lineage differentiation media (right images). Adipogenic lineage of MSC after 14 days is evidenced by Oil Red O staining of 
lipid droplets in the cytoplasm (right images). D. Osteoblastogenic differentiation of extensive calcium mineralized matrix was assessed 
after 21 days using 2% Alizarin Red to detect osteoblasts (right images). Images were captured with a Leica DFC300Fx camera on an 
inverted phase contrast Leica microscope, using 10X objective and Leica IM50 image-acquisition software Version 4. E. Production of 
angiopoietin-2 (Ang-2) and osteopontin (OPN) secreted by MSC in monolayer 2D or hydrogel-based 3D models after 5 days was analyzed 
by multiplex luminex technology.
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molecules in 3D versus 2D models, as determined by flow 
cytometry analysis (Figure 3B, right). Consistent with 
the expression of various ECM molecules, expression of 
β1 and α4 subunits of VLA-4 integrin were also higher 
in 3D compared to 2D MSC cultures, as determined by 
immunofluorescence staining of confocal microscopy and 
confirmed by flow cytometry analysis (Supplementary 
Figure S1). Furthermore, formation of dimeric active 
integrins including α5β1 (VLA-5), α2β1 (VLA-2), and 
αvβ3 (VLA-3) on the MSC surface when engaged by 
these ECM molecules, which induces MM proliferation 
and survival, was also increased in the 3D versus 2D MSC 
model, as confirmed by confocal microscopy and flow 
cytometry analysis (Figure 3C).
Figure 3: ECM-, integrin- and niche related microenvironment in 3D vs 2D MSC models. A. Production of cytokines IL-6 
(p=0.002) and IL-8, chemokine MCP-1, and growth factors IGFBP-1, HGF and VEGF (p<0.001) secreted by 2D vs 3D MSC conditions 
after 5 days was determined by luminex technology. B. Confocal microscopy analysis (left) and scatter plots from flow cytometry analysis 
(right) after 5 days of culture of MSC from 34 MM patients show expression of ECM molecules fibronectin, laminin, vitronectin, collagen 
IV and collagen I in 3D MSC vs 2D models (p<0.001). Green fluorescence represents expression of ECM molecules; nuclei are identified 
by DAPI staining (blue color). Each dot represents MSCs from one MM patient. C. The expression of active integrins α5β1 (VLA-5 
receptor for fibronectin, green), α2β1 (VLA-2 receptor for collagens, green) and αvβ3 (VLA-3 receptor for vitronectin) on the surface of 
2D vs 3D MSC was determined by confocal microscopy and flow cytometry analyses (p<0.001). Nuclei are identified by DAPI staining 
(blue color). Each triangle represents MSCs from one MM patient. D. Expression of N-cadherin, nestin, and CXCL12 was assessed by flow 
cytometry analysis on MSC from 34 MM patients after 5 days of culture in 2D vs 3D conditions (p<0.001).
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3D MSC form functional myeloma niche
To mimic the functional myeloma niche, key 
hematopoietic and/or neoplastic niche molecules including 
N-cadherin and nestin, as well as the interactions of MM 
cells with MSCs in the niche via CXCL12/CXCR4 axis, 
were next investigated. MM patient-derived MSC cultured 
in 3D versus 2D models showed significantly increased 
expression of N-cadherin and CXCL12, as detected by 
flow cytometry analysis. In contrast, expression of nestin 
was significantly decreased in 3D versus 2D MSC models 
(Figure 3D). Moreover, levels of both soluble Tie-2 
receptor (sTie-2) and stem cell factor (SCF), functionally 
implicated in the HSC niche, were higher in 3D compared 
to 2D MSC cultures. Similarly, higher levels of human 
epidermal growth factor receptor 2 (sHER2neu) and 
soluble epidermal growth factor receptor (sEGFR) were 
evident after 5 days in 3D versus 2D MSC cultures, 
assessed using multiplex luminex based technology 
(Supplementary Figure S2).
3D MSC up-regulate bone-formatting genes/
form osteogenesis
We next compared differences in gene expression 
analysis in 3D versus 2D MSC models. Unsupervised 
analyses of gene expression profiles of SMM (N=5) 
and ND MM (N=4) showed significant differences in 
3D versus 2D models, evidenced by two major distinct 
clusters in heat map (Figure 4A). Several major signaling 
pathways implicated in cancer, cell cycle- regulation, 
and adhesion were upregulated in 2D compared to 
3D MSC models (Figure 4B). The most significantly 
upregulated genes in 3D versus 2D MSC were in the 
signaling pathway mediating endochondral ossification 
(Figure 4C). The highest upregulation was detected 
in matrix metallopeptidase 13 (MMP13), followed by 
bone sialoprotein (SPP1), matrix gla protein (MGP), 
and ADAM metallopeptidase with thrombospondin type 
1motif 4 (ADAMTS4), as well as slightly increased 
expression of Runt-related transcription factor 2 (RUNX2) 
and fibroblast growth factor receptor 1 (FGFR1) genes; 
in contrast, calmodulin 1 (CALM1) was significantly 
down-regulated. Furthermore, real-time RT-PCR analyses 
comparing MM patient (SMM, ND, REL, REF; N=23)-
derived MSC cultured in 3D versus 2D models confirmed 
significantly upregulated MMP13, SPP1, ADAMTS4, 
and MGP with a slight increase of RUNX2 and FGFR1 
expression; in contrast, expression of CALM1 was 
significantly decreased (Figure 4D), consistent with 
activation of osteogenesis in the 3D MSC model.
3D MSC co-culture with BM mononuclear cells/
MM cells
We next co-cultured BM mononuclear cells (MNC) 
from MM patients (N=12) with MM patient-derived MSC 
for 7 days in 2D versus 3D models. MNC were either 
thawed (autologous model; Figure 5A) or freshly isolated 
(allogeneic model; Figure 5B), evaluated for plasma 
cells (PC) expression before co-culture (black column), 
and then seeded either into hydrogel based 3D (red) or 
monolayer 2D (grey) models in which MSC had been 
maintained for 5 days in culture. In autologous MNC co-
cultures with MSC, we noted increased proliferation of 
PC in 7 of 12 MM patients in both 3D and 2D models, 
with slightly higher proliferation rate in the 3D MSC 
model (Figure 5A). Moreover, MSC in 3D versus 2D 
conditions co-culture with allogeneic MNC from MM 
patients (N=12) similarly showed significant increase 
of PC in 3D versus 2D models in 9 of 12 MM patients 
(Figure 5B). Further phenotypic characterization of these 
cells showed that CXCR4 expression was significantly 
increased on PC co-cultured in 3D versus 2D MSC models 
(Figure 5C). Furthermore, expression of side population 
(SP) cells representing “stem-like” features of MM cells 
[20] was determined by Hoechst 33342 staining and 
gating on CFSE positive MM cells in co-cultures with 
MM patient-derived MSC; low Hoechst stained cells 
were identified as SP cells (Figure 5D). The SP fraction 
of MM cell lines (OPM1, KMS11 and OCIMY5) was 
significantly increased in 3D versus 2D MCS co-culture 
models at 3 days. We also co-cultured MSC in 3D versus 
2D models with allogeneic MNC from MM patients 
(N=5) to assess immune subpopulation distribution 
using mass cytometry and spanning-tree progression 
analysis of density-normalized events (SPADE) (Figure 
6). No significant differences in immune cell frequencies 
were detected between 2D versus 3D models; however, 
decreased T cells and mature granulocytes were detected 
in 3D versus 2D models (Supplementary Figure S3A). Of 
note, median expression of immunophenotypic markers on 
T cells, NK cells (Supplementary Figure S3B); mature B 
cells, PC (Supplementary Figure S3C); monocyte and their 
precursors, mDC, granulocytes as well as their precursor 
(Supplementary Figure S3D); and MSC (Supplementary 
Figure S3E) significantly differs in 3D versus 2D models. 
Further evaluation of T cells including TH (helper) and 
TC (cytotoxic) cell populations as well as both naïve 
and memory T cells by SPADE analyses revealed that 
no significant differences in cell frequencies were 
detected in these models (Supplementary Figure S4A); 
however, changes in median expression of T cell specific 
markers were observed between 2D versus 3D models 
(Supplementary Figure S4B). The similar distribution 
pattern of immune cell subsets in both models suggests 
that they may be useful to assess immune profile before 
and after novel targeted and immune therapies.
3D co-culture system confirms MM resistance
To test drug efficacy in the 3D model, MSC from 10 
MM patients were cultured in 3D versus 2D models for 5 
days, and then allogeneic drug resistant CFSE fluorescent 
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dye-labelled patient PC were added with novel and 
conventional anti-MM drugs for 3 days. PC co-cultured 
with 3D versus 2D MSC did not reveal any significant 
differences after pomalidomide (POM) treatment; 
however, PC in 3D co-cultures were significantly more 
resistant to lenalidomide (LEN) and thalidomide (THAL) 
than in 2D MSC model (Figure 7A). Similarly, resistance 
to proteasome inhibitor bortezomib (BTZ) was shown 
in 3D versus 2D MSC model. In contrast to bortezomib, 
treatment with carfilzomib (CFZ) showed high percentage 
of apoptotic and necrotic PC in both 2D and 3D co-culture 
systems (Figure 7B). Resistance to doxorubicin (DOXO) 
and dexamethasone (DEX) was also observed in both co-
culture systems, and resistance to melphalan (MELPH) 
treatment was observed in the 3D vs 2D model systems 
(Figure 7C). Similarly, freshly isolated MNC from BM of 
MM patients (N=4) were cultured with allogeneic MSC 
in 3D versus 2D conditions, followed by treatment with 
POM or CFZ for 7 days (Figure 7D). Resistance to POM 
or CFZ was observed in 3D versus 2D models in MM 
patients 2 or 4 and 1, respectively. While these data reflect 
clinical resistance to these agents, ongoing prospective 
trials are validating their predictive value to conventional, 
novel and immune therapies in larger patient numbers.
Figure 4: Gene expression analysis in 3D vs 2D MSC models. A. Unsupervised gene expression analysis using GeneSpring 
software of MSC obtained from SMM (N=5) and ND (N=4) MM patients after 5 days of culture in 3D vs 2D models. B. Major signaling 
pathways with most significantly modulated genes in 2D versus 3D MSC are listed from highest to lowest p values. C. Unsupervised 
gene expression analysis of the 7 genes (MMP13, SPP1, ADAMTS4, MGP, CALM1, RUNX2, and FGFR1) altered in MSC in 3D vs 2D 
models obtained from SMM (N=4) and ND (N=4) MM revealed increased endochondral ossification signaling pathway using GeneSpring 
software. D. Fold expression difference of RUNX2 (p=0.425), FGFR1 (p=0.003), MGP (p=0.016), ADAMTS4 (p≤0.001), CALM1 
(p≤0.001), MMP13 (p≤0.001), and SPP1 (p≤0.001) genes in 3D vs 2D cultures of MSC from SMM and ND MM (red color, N=13) and 
REL and REF MM (grey color, N=10) patients were analyzed by real-time RT-PCR analyses using Bio-Rad Software. Normalized fold 
expression difference was calculated by the ΔΔCq method.
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DISCUSSION
In the BM, specialized microdomains termed 
“niches” regulate hematopoietic stem cells (HSC) 
function [21]. These specific HSC niches play essential 
roles in controlling the balance in hematopoiesis 
through heterologous cell-cell interactions, secreted 
factors, extracellular matrix molecules (ECM), physical 
parameters, as well as immunological and metabolic 
control. Increasing evidence suggests that, like stem 
cells, tumor cells do not depend solely on cell-intrinsic 
events, but instead rely heavily on the microenvironment 
or “niche” to maintain their growth, survival, and drug 
resistance [22]. In MM, interactions between malignant 
plasma cells and stromal/mesenchymal stem cells 
(MSCs) embedded in an extracellular matrix make up the 
unique neoplastic BM milieu that promotes the disease 
development and progression. Therefore, the tumor 
microenvironment is recognized both as an essential 
factor in MM biology and target for novel therapeutic 
strategies [23].
Several novel experimental drugs have not been 
translated to the clinic due to preclinical drug evaluation 
involving only tumor cells without consideration of the 
role of the tumor microenvironment. Therefore, several 
groups have developed stromal cell-MM cell co-culture 
models as tools for novel drug screening [11, 12]. 
However, these models lacked the 3D architecture of the 
BM, and therefore fail to mimic the in vivo niche. More 
recent studies have elucidated the importance of using 
Figure 5: BM primary MM cells co-culture in 3D vs 2D MSC models. A. Thawed mononuclear cells (MNC) from 12 MM 
patients were cultured for 7 days together with autologous MSC maintained in culture for 5 days before in 2D vs 3D co-culture conditions. 
Plasma cells (PC), identified by co-expression of CD38 and CD138 differed before co-culture (black column) and after 7 days in 2D vs 
3D co-culture systems (grey and red columns) (p=0.004). Holm-Sidak method revealed significant differences in 3D vs before co-culture 
(p=0.003). B. Freshly isolated allogeneic MNC from 12 MM patients were cultured for 7 days with patient-derived MSC in 2D vs 3D co-
culture models (grey and red columns). PC significantly differed, before co-culture (black column) and after 7 days in 2D vs 3D co-culture 
models (p<0.001), Holm-Sidak method revealed significant differences in 3D vs before co-culture and 3D vs 2D MSC models (p<0.001). 
C. Expression of CXCR4 on both autologous and allogeneic PC (N=24) in 2D vs 3D co-culture models (p=0.013) was evaluated by flow 
cytometry. D. SP cells of MM cell lines, identified by Hoechst 33342 staining of flow cytometry, were measured after 3 days of co-culture 
of MSC from 12 MM patients in 3D vs 2D conditions with OPM1 (p=0.014), KMS11 (p=0.044) and OCIMY5 cells (p<0.001) labeled with 
CFSE dye.
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Figure 6: Detection of immune cell subsets in 3D model by SPADE analysis. SPADE plots of bone marrow MNC of 
representative MM patient co-culture with allogeneic MSC in 3D model. SPADE clustering was performed on all samples (N=5) before, 
and after co-culture in 3D vs 2D models simultaneously to generate a single tree structure for all samples. MNC before co-culture were 
used as baseline for both 2D and 3D co-culture models. All cell events from each sample were then mapped to the common tree structure. 
SPADE organized cells to the cluster in the tree by a hierarchy of related phenotype. The size of each node is correlated to the fraction 
of cells mapping to the node. Each node of the SPADE tree is colored to median expression of the indicated markers: from low (blue 
color) to high (red color) expression. Unsupervised clustering analyses define the main immunophenotypic populations in SPADE tree, 
based on selected clustering cell surface markers. Immunophenotypic subpopulation identification was performed manually by grouping 
of nodes on the basis of the median marker expression level of each node, and based on analysis of the relevant biaxial plots into: T cell 
(CD3+CD4+CD8+CD7+), NK (natural killer) cell (CD3-CD7+CD45-RA+CD56+/-CD16+/-), B cell precursor (CD38+CD19-CD123+/-), 
mature B cell (CD38+CD19+), PC (CD45- CD38++CD138+cyto kappa+/cyto lambda-), monocyte precursor (CD33+/-CD11b+/-), mature 
monocyte (HLA-DR+CD33+CD11b+CD11c+CD15-CD14+), basophil (HLA-DR-CD38+CD123+), mDC (myeloid dendritic cell; HLA-
DR+ CD123-), pDC (plasmacytoid dendritic cell; HLA-DR+ CD123+), granulocyte precursor (HLA-DR- CD11bdimCD11cdim), mature 
granulocyte (HLA-DR-CD33+/-CD11b+CD11c+CD15+CD16+), and MSC (CD73+CD90+CD105+CD63+). Representative SPADE plots 
for specific markers are shown, such as main hematopoietic marker CD45, then CD11b, CD3, CD38, cyto kappa and CD73. + = positive
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Figure 7: MM resistance to anti-MM agents in 3D vs 2D MSC models. MSC from 10 MM patients were maintained in culture 
for 5 days either in 2D vs 3D culture conditions, and then co-cultured together with plasma cells (PC) labeled with CFSE. These PCs, 
obtained from the pleural effusion of a MM patient with resistant disease, were treated with A. immunomodulatory drugs: pomalidomide 
(POM), lenalidomide (LEN) and thalidomide (THAL) at concentrations 1, 2 and 4 μM; B. proteasome inhibitors: bortezomib (BTZ) 
and carfilzomib (CFZ) at concentrations 5, 10 and 20 nM; or C. conventional anti-MM therapies: doxorubicin (DOXO; 1, 2 and 4 μM), 
dexamethasone (DEX; 1, 2 and 4 μM), and melphalan (MELPH) at concentrations 5, 10 and 20 μM. After 3 days, cells were stained with 
AnnexinV/7-AAD and analyzed by a FACS Canto II flow cytometer using a 96-well format. The percentage of apoptotic (AnnexinV+7-
AAD-) and necrotic (AnnexinV+7-AAD+) CFSE positive PCs is shown in the graphs. D. Freshly isolated MNC from 4 MM patients 
were cultured with allogeneic MM patient-derived MSC in 2D vs 3D co-culture models, and then treated with POM (4 μM) and CFZ 
(20 nM) for 7 days. BM samples tested were obtained from patients with MM: patient 1 had relapsed MM (REL) previously treated with 
CFZ-LEN-DEX; patient 2 had smoldering MM (SMM) who had not been treated; patient 3 had newly diagnosed MM (ND) treated with 
induction regimen cyclophosphamide-BTZ-DEX; and patient 4 had relapsed/refractory MM (REF), previously treated with POM-BTZ-
DEX regimen. Expression of PC was evaluated by flow cytometry, and fold change of PCs relative to control under respective 2D vs 3D 
co-culture conditions is shown.
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3D, rather than 2D, models to create an experimental 
system recapitulating the specialized properties of the 
marrow microenvironment [24]. Specifically, 3D cultures 
using ECM molecules [13], hyaluronic acid [25], and 
specialized scaffolds like gelatin sponge [14] or silk [15] 
have been introduced in vitro; however, these models lack 
mineralization and do not mimic the strength, rigidity, or 
complexity of in vivo. Other more sophisticated/advanced 
approaches, such as microfluidic ossified tissue [16, 
17] or RCCS™ bioreactor-based culture [18], remain 
very technically challenging. Moreover, several murine 
humanized MSC-MM cell interaction models have been 
developed using the SCID-hu model [26, 27], or based 
on scaffolds such as 3D poly-ε-caprolactone polymeric 
scaffolds [28] or biphasic calcium phosphate [29]; 
however, these models are costly, time-consuming, and 
exhibit drug distribution limitations. Therefore, more 
studies are needed to develop models of the architecture 
of BM, facilitating studies of MM pathophysiology and 
novel drug development.
Several similarities between the normal HSC niche 
and the MM niche have been described. To develop 
an experimental system recapitulating the specialized 
properties of the neoplastic BM microenvironment, we 
therefore first expanded and modified the HSC niche 
model [30]. Specifically, we first introduced new 3D 
co-culture ex-vivo models composed of MM patient-
derived MSC in hydrogel 3D system for co-culture with 
patient MM BM cells. In the field of tissue engineering, 
creating hydrogel based 3D culture systems, a network 
of interacting polymer chains that are highly hydrated 
with elasticity similar to natural tissues, with MSCs can 
achieve tissue-like structures in vitro. Importantly, MM 
patient-derived MSC, which represent the main cellular 
component of the marrow niche, in the hydrogel based 
system promote a high degree of mineralization and 
differentiation and create MM niche-like structures in 
vitro. These patient-derived MSC supply the appropriate 
niche scaffold for MM growth, survival, and homing. 
Moreover, MSCs are clonogenic and can be expanded ex 
vivo without any apparent modification in phenotype and 
loss of function [31] and therefore represent a promising 
strategy for tissue engineering, repair of damaged tissue, 
and gene therapy.
Previous reports show that myeloma-associated 
MSC demonstrate significant abnormalities compared 
to healthy donors MSCs, including ECM, integrin and 
cytokine modulation changes [32–34]. It has been reported 
that there are 0.01-0.001% of MSCs in the healthy bone 
marrow. Our data showed varied distribution of MSC 
population (defined by co-expression of CD73, CD90 
and CD105 and negative for all hematopoietic markers, 
such as lineage markers as well as CD34 progenitors) 
in differently treated MM patients (REL and REF MM 
patients) compared to untreated MM patient samples in 
premalignant (SMM) or newly diagnosed (ND) active 
MM stages. Interestingly, higher MSC population was 
revealed in treated REL and REF MM samples (0.01-
1.3%), suggesting an impact of anti-MM therapies on 
the tumor microenvironment. Moreover, significantly 
less (more than 15 times) amount of MSCs (≤1.3%) was 
observed compared to plasma cells (≤20%, defined by 
co-expression of CD38 and CD138; data not shown), 
confirming the necessity for the MSC expansion to study 
MM disease in their presence.
Three criteria to define MSCs have been 
determined: adherence to plastic; expression of CD73, 
CD90 and CD105; and differentiation into three-lineage 
stages [19]. BM-derived stromal progenitors also have 
been termed mesenchymal stem cells due to their specific 
capability of generating multiple mesenchymal lineages 
[31]. Our data showed that 3D MSC maintained their 
multi-lineage differentiation potential toward adipocytes 
and osteoblasts, as well as conserved phenotype defined 
by co-expression of CD73, CD90 and CD105. Moreover, 
3D MSC showed calcium mineralization of clusters 
supporting differentiation towards the osteoblastogenic 
lineage, which was functionally confirmed by increased 
production of OPN and angiopoietin. OPN and 
angiopoietins are regulators of osteoblast-mediated HSC/
MM cells maintenance, and are expressed by osteoblasts 
[35]. Furthermore, our 3D MSC model showed increased 
expression of N-cadherin as well as up-regulation of 
bone-related genes including MMP13, supporting 
early osteoblast differentiation. Similarly, activation of 
osteogenesis in the 3D MSC model versus 2D monolayer 
cultures is associated with significant overexpression 
of endochondral ossification pathway genes including 
SPP1, MGP and ADAMTS4. These results are consistent 
with the observation that pre-osteoblast/early osteoblast 
precursors increase proliferation of MM cells, in 
contrast to mature osteoblasts which form mineralized 
nodules and suppress the growth and proliferation of 
MM cells [36–39]. Moreover, MSCs are negative for 
hematopoietic markers CD45, CD34 and other lineage 
differentiation markers [19]. We here confirmed that 
the 3D MSC clusters lacked expression of CD45, CD34 
and HLA-DR, as well as lineage differentiation markers 
similar to 2D MSC (data not shown). Furthermore, they 
display common expression profile markers including 
CD29, CD49c, CD166 and HLA-ABC, which are 
similarly detected in both our systems. Nevertheless, 
significant differences have been shown in expression 
of CD36, CD106, CD146 and others [40]. Similarly, 
3D MSC lacked expression of CD146, which suggests 
similarities with CD45-CD146-negative expression of 
MSC located in the endothelial niche [41]. Moreover, 
CD271 downregulated expression in 3D MSC suggests 
MSC differentiation from CD271+ progenitors [42]. 
Therefore, our 3D MSC model mimics the BM niche, 
allowing for further studies of MM biology and novel 
therapeutic strategies.
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Indirect communication between tumor cells 
and MSCs is mediated by secretion of growth factors, 
chemokines, and cytokines. IL-6 remains the prototypical 
growth and survival factor in MM [43]. In addition to IL-
6, other cytokines and/or chemokines also contribute to 
the cross-talk between stroma and MM cells including 
IL-8, RANTES (regulated and normal T cell expressed 
and secreted), IL-1β, TNF-α, IGF-1 (insulin-like growth 
factor-1) and others [6]. VEGF also modulates growth, 
survival and migration of myeloma cells in an autocrine 
manner via VEGFR-1 [44]. Moreover, the tumor 
microenvironment releases growth factors for myeloma 
cells including HGF, matrix metalloproteinases (MMPs), 
fibroblast growth factor-2, MCP-1 (monocyte chemotactic 
protein-1), and others [45]. Our data showed that MSC 
in the 3D model support production of pro-inflammatory 
interleukins IL-6 and IL-8; MCP-1; IGFBP-1; as well as 
pro-angiogenic growth factors VEGF and HGF involved 
in progression of MM. Moreover, production of sHER2/
neu and sEGFR, growth factors of aggressive cancers, 
was also assessed in 3D MSC. Our study suggests that 
recruitment of MM cells and other normal hematopoietic 
cells and non-hematopoietic cells and their progeny to the 
MM niche leads to a complex milieu of growth factors, 
chemokines, and ECM that can form a functional niche. 
Therefore, deeper understanding the phenotypic features 
and molecular signatures of the neoplastic BM niche in 
MM may provide the framework for future development 
of new treatment strategies targeting biology of both MM 
cells and their BM niche.
Key signaling regulatory molecules and cell-cell 
crosstalk interactions involved in MM are directly adopted 
from the normal HSC niche. The most abundant acellular 
component of the BM niche is composed of ECMs 
including fibronectin, laminin, collagen, and hyaluronan. 
Abnormal ECM or ECM stiffness deregulates the tumor 
microenvironment by facilitating angiogenesis and 
inflammation [46]. Moreover, ECMs mediate adhesion, 
migration, and cell adhesion-mediated drug resistance of 
MM cells by binding to adhesion molecules [47]. HSC/
MM cell adhesion is mediated via the integrin family 
including very late antigen 4 (VLA-4, composed of α4 
and β1 subunits) and VLA-5 (active dimer of α5 and β1 
subunits) [48, 49]. Our 3D model showed upregulation 
of ECM molecules and integrins (α2β1, α5β1, and αvβ3) 
which are mediators of MM progression and resistance to 
apoptosis. In addition, the CXCL12-CXCR4 axis signaling 
pathway plays an important role in MM maintenance and 
homing, with high expression of CXCL12 on stromal 
cells acting as a chemoattractant for both HSC/MM 
cells expressing high level of CXCR4 [50]. In our 3D 
model, we observed significantly higher expression of 
CXCL12 on myeloma derived-MSCs and upregulated 
CXCR-4 expression on plasma cells, as well as significant 
production of sTie-2 receptor and SCF, reflecting the 
MM niche.
Normal PC are terminally differentiated and unable 
to proliferate [51]. Similarly, primary malignant PCs 
have a low proliferation index in vitro, whereas the tumor 
microenvironment promote MM survival and proliferation 
[3]. Although MM cell lines can proliferate in vitro, 
they are mostly derived from plasma cell leukemia and 
have lost BM dependency. Therefore, it is questionable 
how far we can force the malignant PC to proliferate. 
Our data showed that both ex vivo conventional 2D 
monolayer and 3D MSC co-culture systems increased 
proliferation of primary malignant PC, with a higher 
proliferation index in the 3D model. Moreover, the 
impact of autologous and allogeneic conditions did not 
reveal any significant differences in proliferation of PC, 
suggesting that autologous MM derived-MSC may not 
be required in the co-culture system. Interestingly, SP 
fraction representing stem cell-like cells was upregulated 
in MM cells when co-cultured with 3D MSC versus the 
2D system. Finally, CXCR4 was significantly increased 
on PC in the 3D system and previous data showed CXCR4 
expression increased in SP cells in co-culture with MSC 
[52], suggesting MM homing and adhesion mediating their 
survival.
Progression of MM is associated with immune 
suppression that interferes with tumor elimination 
and an effective antitumor response. Recent evidence 
indicates that interactions among tumor cells, stromal 
cells, and immune cells regulate anti-tumor immunity. 
Specifically, stromal signatures can predict for survival 
[53], as can immune T cells and macrophages in the tumor 
microenvironment [54]. Moreover, interactions among 
the malignant clone, stroma, and immune cell subsets 
engender an immunosuppressive tumor microenvironment 
[55]. Here we therefore incorporated not only MSC/
stromal and tumor cells in our 3D model, but also immune 
cells. Applying the CyTOF technology resulted in high-
dimensional data that allows for the quantification of 
phenotypically and functionally distinct immune cell 
subsets. Importantly, we used an antibody panel tailored 
to innate and adaptive immune cells, manual gating 
strategies, as well as clustering algorithm by SPADE 
approach, to define immune cell subsets. Our results 
demonstrated that distribution of immune cells can be 
readily assessed in our 3D MSC co-culture model, which 
will allow for defining both the role of immune accessory 
cells and the effects of novel chemo-/immune-based 
therapies.
Although commonly sensitive to novel therapies, 
MM cells develop resistance underlying disease relapse. 
The emergence of resistance may be due to very complex 
microenvironmental-tumor cell interactions in bone 
marrow [56]. Therefore, we next evaluated sensitivity of 
MM cells to IMIDs (THAL, LEN and POM); proteasome 
inhibitors (BTZ and CFZ); and conventional drugs (DEX, 
DOXO and MELPH) using our 3D MSC co-culture 
system. Our results showed significant resistance of MM 
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cells to THAL and LEN; BTZ; and conventional anti-MM 
(DEX, DOXO and MELPH) therapies reflecting clinical 
resistance. We next evaluated sensitivity of MM cells from 
4 patients to POM or CFZ in this system, and similarly 
demonstrated profiles reflecting clinical sensitivity versus 
resistance. These preliminary studies need to be validated 
in prospective trials, but do suggest that our 3D co-culture 
system may predict for clinical utility of novel therapies.
In conclusion, in this study we investigated the role 
of the marrow microenvironment in MM. Interactions 
among malignant PC, immune accessory cells, and 
MSC/stromal cells with ECM, integrins, and other niche 
molecules which mediate disease development and 
progression were characterized using a hydrogel based 3D 
ex vivo co-culture system. Importantly, the 3D co-culture 
closely mimics MM marrow physiology and therefore 
provides a model to now explore growth of MM clones 
associated with drug resistance and minimal residual 
disease. Importantly, it may identify novel mechanisms 
to target to interrupt these processes. Ultimately the 3D 
co-culture model may assess tumor cell sensitivity to 
conventional and novel anti-MM therapies, and thereby 
inform single agent or combination individualized therapy.
MATERIALS AND METHODS
Reagents
Thalidomide, lenalidomide, pomalidomide, 
bortezomib and carfilzomib were purchased by Selleck 
Chemicals LLC (Houston, TX, USA). Reserpine, 
doxorubicin, dexamethasone and melphalan were obtained 
from Sigma-Aldrich (St. Louis, MO, USA).
Patient samples and cell cultures
Overall BM samples from 52 patients with 
premalignant condition or MM were studied including: 
smoldering MM (N=8), newly diagnosed MM (N=5), 
relapsed MM (N=23), and relapsed/refractory MM 
(N=16). Approval for these studies was obtained from 
the Dana-Farber Cancer Institute Institutional Review 
Board. All patient samples were collected after informed 
consent in accordance with the Declaration of Helsinki 
protocol. After BM aspiration (Figure 1A, i), fresh BM 
mononuclear cells (MNC) were obtained by ammonium 
chloride based-lyses of red cells (iii), followed by washing 
in phosphate-buffered saline (PBS). Cells were then 
cultured in complete α-MEM (Cellgro, Mediatech, VA, 
USA) supplemented with 5% platelets, 2 U/mL Heparin, 
100 U/mL penicillin, 100 μg/mL streptomycin (Gibco, 
Grand Island, NY, USA), and maintained at 37°C in 5% 
CO2 to generate MSC (iv). After 3 days, the non-adherent 
fraction of MNCs from BM samples was collected and 
frozen, whereas the MSC (adherent fraction) were 
expanded with fresh complete α-MEM added every 3 
days (Figure 1A, iv). In addition, MSC were cultured with 
respective lineage differentiation media, as described in 
Supplemental Methods. MM cell lines were obtained from 
American Type Culture Collection (ATCC; Manassas, VA, 
USA) and maintained in RPMI 1640 medium (Cellgro, 
Mediatech, VA, USA) supplemented with 10% heat-
inactivated fetal bovine serum, 2mM L-glutamine, 100 U/
mL penicillin, and 100 μg/mL streptomycin.
Establishment of 2D and 3D cultures
The MSC (8×104 cells/cm2) were seeded on plastic 
surface in complete Dulbecco’s modified Eagle medium 
(DMEM; Cellgro, Mediatech, VA) supplemented with 
10% heat-inactivated fetal bovine serum, 100 U/mL 
penicillin, 100 μg/mL streptomycin, and maintained at 
37°C in 5% CO2 to establish monolayer (2D) cultures. 
For generation of 3D models, 0.5% PuraMatrix hydrogel 
(5mg/ml; BD Biosciences, San Jose, CA, USA) diluted in 
tissue culture-grade water was placed on the well surface. 
For gelation, complete DMEM medium was slowly and 
carefully added and incubated for 30min at 37°C in 5% 
CO2. After incubation, the medium was changed 2-3 
times over a period of 1 hour to equilibrate the growth 
environment to physiological pH. MSC (8x104 cells/cm2) 
were then seeded on the surface of the pH equilibrated 
hydrogel.
Immuno-fluorescence/mass analyses
Cell surface phenotype of MSC was evaluated by 
11-color multiparametric flow cytometry, as described 
in Supplemental Methods. Expression of PC phenotype 
was determined by flow cytometry analyses. Immune 
subpopulations were detected by mass cytometry 
(CyTOF) analyses of 23 cell surface and 2 intracellular 
phenotypic markers, as described in Supplemental 
Methods. The expression of ECM molecules, integrins, 
and other key niche molecules listed in Supplemental 
Methods was evaluated by immunofluorescence staining, 
using multiparametric flow cytometry and confocal 
microscopy. Multiplex fluorescence bead-based cytokine 
immunoassays were performed for quantification of 
multiple cytokine, chemokine, growth factor, and cancer 
biomarkers, as described in Supplemental Methods. MM 
cell proliferation and drug resistance in co-culture systems 
were evaluated with CFSE and Annexin V-PE apoptosis 
assays using flow cytometry. Functional assays to identify 
SP fractions were detected be Hoechst 33342 dye staining, 
as described in Supplemental Methods.
Molecular profiling analyses
Gene expression of MSC was determined using 
Human Gene 1.0 ST array analyses, as described in 
Supplemental Methods. Reverse transcription polymerase 
chain reaction (RT-PCR) was performed using Tagman 
assays, as described in Supplemental Methods.
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Statistical analyses
Statistical significance of two groups was 
determined by parametric-paired t-test (mean comparison) 
and non-parametric-Wilcoxon signed rank test (median 
comparison). The differences in the mean and median 
values among three and more paired groups were tested 
using one way repeated measures (RM) analysis of 
variance (ANOVA) and RM ANOVA on ranks (Friedman 
test), respectively. A multiple comparison procedures, 
the Holm-Sidak method and the Tukey test, were used to 
isolate the group or groups that differ from the others. A 
nonparametric Kruskal-Wallis ANOVA on ranks was used 
for comparison of unpaired samples. In all statistical tests, 
p values <0.05 were considered significant.
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